Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Shares Sold by MetLife Investment Management LLC

Posted by on Mar 2nd, 2023

MetLife Investment Management LLC reduced its position in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN – Get Rating) by 3.7% in the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 26,839 shares of the specialty pharmaceutical company’s stock after selling 1,030 shares during the quarter. MetLife Investment Management LLC’s holdings in Supernus Pharmaceuticals were worth $909,000 at the end of the most recent reporting period.

Several other hedge funds have also recently added to or reduced their stakes in SUPN. Polaris Capital Management LLC raised its stake in Supernus Pharmaceuticals by 8,769.9% in the 2nd quarter. Polaris Capital Management LLC now owns 2,918,196 shares of the specialty pharmaceutical company’s stock valued at $45,611,000 after purchasing an additional 2,885,296 shares during the last quarter. Mesirow Institutional Investment Management Inc. purchased a new stake in Supernus Pharmaceuticals in the 3rd quarter valued at $11,004,000. International Biotechnology Trust PLC grew its holdings in Supernus Pharmaceuticals by 3,357.7% in the 3rd quarter. International Biotechnology Trust PLC now owns 297,500 shares of the specialty pharmaceutical company’s stock valued at $10,070,000 after buying an additional 288,896 shares in the last quarter. Goldman Sachs Group Inc. grew its holdings in Supernus Pharmaceuticals by 108.1% in the 1st quarter. Goldman Sachs Group Inc. now owns 550,081 shares of the specialty pharmaceutical company’s stock valued at $17,779,000 after buying an additional 285,737 shares in the last quarter. Finally, Millennium Management LLC purchased a new stake in Supernus Pharmaceuticals in the 2nd quarter valued at $7,063,000. 99.82% of the stock is owned by institutional investors and hedge funds.

Supernus Pharmaceuticals Trading Up 4.4 %

NASDAQ SUPN opened at $39.25 on Thursday. The stock has a market cap of $2.12 billion, a PE ratio of 38.11 and a beta of 0.99. Supernus Pharmaceuticals, Inc. has a twelve month low of $24.95 and a twelve month high of $42.09. The stock has a fifty day simple moving average of $39.04 and a 200-day simple moving average of $36.05.

Supernus Pharmaceuticals (NASDAQ:SUPN – Get Rating) last released its quarterly earnings results on Tuesday, February 28th. The specialty pharmaceutical company reported $0.43 earnings per share for the quarter, missing analysts’ consensus estimates of $0.73 by ($0.30). The business had revenue of $167.33 million for the quarter, compared to analysts’ expectations of $180.38 million. Supernus Pharmaceuticals had a return on equity of 4.51% and a net margin of 5.72%. The business’s revenue for the quarter was up 5.2% compared to the same quarter last year. During the same quarter in the prior year, the company posted $0.04 earnings per share. Research analysts predict that Supernus Pharmaceuticals, Inc. will post 1.63 EPS for the current year.

Wall Street Analysts Forecast Growth

Several analysts have issued reports on SUPN shares. StockNews.com upgraded Supernus Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a report on Tuesday. TheStreet upgraded Supernus Pharmaceuticals from a “c+” rating to a “b+” rating in a report on Tuesday. Finally, Piper Sandler upped their target price on Supernus Pharmaceuticals from $40.00 to $47.00 and gave the company an “overweight” rating in a report on Monday, January 23rd.

Insider Transactions at Supernus Pharmaceuticals

In related news, CEO Jack A. Khattar sold 13,532 shares of the firm’s stock in a transaction dated Thursday, February 2nd. The stock was sold at an average price of $42.05, for a total transaction of $569,020.60. Following the completion of the transaction, the chief executive officer now directly owns 804,142 shares in the company, valued at approximately $33,814,171.10. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. In related news, CEO Jack A. Khattar sold 25,446 shares of the firm’s stock in a transaction dated Tuesday, January 17th. The stock was sold at an average price of $40.03, for a total transaction of $1,018,603.38. Following the completion of the transaction, the chief executive officer now directly owns 791,173 shares in the company, valued at approximately $31,670,655.19. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Jack A. Khattar sold 13,532 shares of the firm’s stock in a transaction dated Thursday, February 2nd. The shares were sold at an average price of $42.05, for a total value of $569,020.60. Following the transaction, the chief executive officer now owns 804,142 shares of the company’s stock, valued at $33,814,171.10. The disclosure for this sale can be found here. In the last ninety days, insiders sold 56,308 shares of company stock worth $2,261,264. 7.99% of the stock is currently owned by company insiders.

Supernus Pharmaceuticals Profile

(Get Rating)

Supernus Pharmaceuticals, Inc engages in the development and commercialization of products for the treatment of central nervous system diseases. It offers Trokendi XR, Oxtellar XR, APOKYN, XADAGO, and MYOBLOC products. The company was founded by Jack A. Khattar on March 30, 2005 and is headquartered in Rockville, MD.

Featured Articles

Institutional Ownership by Quarter for Supernus Pharmaceuticals (NASDAQ:SUPN)

Receive News & Ratings for Supernus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Supernus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.